Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)

Blood

Volumn 101, Issue 6, 2003, Pages 2125-2131

  Del Poeta, Giovanni ^a   Venditti, Adriano ^a   Del Principe, Maria Ilaria ^a   Maurillo, Luca ^a   Buccisano, Francesco ^a   Tamburini, Anna ^a   Cox, Maria Christina ^a   Franchi, Annibale ^a   Bruno, Antonio ^a   Mazzone, Carla ^a   Panetta, Paola ^a   Suppo, Giovanna ^a   Masi, Mario ^a   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; MITOCHONDRIAL PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; SURVIVAL;

EID: 0037443479     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1714     Document Type: Article

References (46)

1. Del Poeta G, Stasi R, Aronica G, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996;5:1997-2004.
2. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996;87:2464-2469.
3. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 1995;85:186-193.
4. Baker S, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene. 1998;17:3261-3270.
5. Rokhlin OW, Glover RA, Cohen MB. Fas mediated apoptosis in human prostate carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res. 1998;58:5870-5875.
6. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from the mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132-1136.
7. Saleh A, Srinivasula SM, Acharay S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem. 1999;274:17941-17945.
8. Oltval ZN, Milliman CL, Korsmeyer K. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
9. Campos L, Rouault J-P, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
10. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 1997;11:2075-2078.
11. Ong YL, McMullin MF, Bailie KEM, Lappin TRJ, Jones FGC, Irvine AE. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol. 2000;111:182-189.
12. Stoetzer OJ, Nussler V, Darsow M, et al. Association of bcl-2, bax, bcl-xL and interleukin-1 -beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia. 1996;10:S18-S22.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:620-625.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol. 1991;78:325-329.
15. Del Poeta G, Stasi R, Venditti A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia. 1994;8:388-394.
16. Stasi R, Del Poeta G, Masi M, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet. 1993;67:28-34.
17. Samuels BL, Larson RA, Le Beau MM, etal. Specific chromosome abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vitro. Leukemia. 1988;2:79-83.
18. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes regulators of cell death. Blood. 1992;80:879-886.
19. Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ. Movement of bax from cytosol to mitochondria during apoptosis. J Cell Biol. 1997;139:1281-1292.
20. De Witte T, Suciu S, Zittoun R, et al. The type of antracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-GIMEMA AML-10 randomized trial [abstract]. Blood. 2000;96(suppl 1):2167a.
21. Suciu S, Zittoun R, Mandelli F, et al. Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) ≤ 45 yrs old in first CR: results of the EORTC-GIMEMA AML-10 trial [abstract]. Blood. 2001;98(suppl 1):2010a.
22. Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani PL, Tura S. Fludarabine + ARA-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia. 1994;8:2076-2082.
23. Maung ZT, MacLean FR, Reid MM, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol. 1994;88:105-109.
24. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood. 1997;89:243-255.
25. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerization with Bax. Proc of Natl Acad Sci U S A. 1995;92:7834-7838.
26. Provinciali M, Di Stefano G, Ciavattini A, Garzetti GG. Baseline apoptosis of tumour cells as a response predictor to chemotherapy. J Natl Cancer Inst. 1997;89:889-890.
27. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL-2. Proc Natl Acad Sci U S A. 1993;90:3516-3520.
28. Zhou P, Quian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 1997;89:630-643.
29. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998;91:991-1000.
30. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood. 2002;100:1810-1816.
31. Chatterjee D, Han Z, Mendoza J, et al. Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bcl-xL. Cell Growth Differ. 1997;8:1083-1089.
32. Boudard D, Vasselon C, Bertheas MF, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol. 2002;70:115-125.
33. Del Poeta G, Venditti A, Aronica G, et al. Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes. Eur J Histochem. 1997; 41(suppl 2):11-12.
34. Delia D, Aiello A, Soligo D, et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 1992;79:1291-1298.
35. Karakas T, Maurer E, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9:159-165.
36. Bradbury DA, Russel NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol. 1995;91:374-379.
37. Lee EJ, Yang J, Leavitt RD, et al. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia. 1992;6:1203-1209.
38. Simmons PJ, Aylett GW, Niutta S, To B, Juttner CA, Ashman LK. C-kit is expressed by primitive human haemopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine supplemented culture. Exp Hematol. 1994;22:157-165.
39. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of PI3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol. 1998;8:779-782.
40. Deng G, Lane C, Kornblau S, et al. Bcl-2 and bcl-xl are expressed at higher levels in poor prognosis (monosomy 5 and monosomy 7) acute myeloid leukemia (AML) cells than in good prognosis inversion 16 and t(8;21) AML cells [abstract]. Proc Am Assoc Cancer Res. 1996;37:22.
41. Kornblau SM, Vu HT, Ruvolo P, et al. Bax and PKCα modulate the prognostic impact of Bcl-2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000;6:1401-1409.
42. Pepper C, Hoy T, Bentley DP, Bcl-2/bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro and clinical drug resistance. Br J Cancer. 1997;76:935-938.
43. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2 related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932-3938.
44. Andreeff M, Jiang S, Zhang X, et al. Expression of Bcl-2 related genes in normal and AML progenitors changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881-1892.
45. Shinobu N, Maeda T, Aso T, et al. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J Biol Chem. 1999;274:17003-17010.
46. Del Poeta G, Venditti A, Maurillo L, et al. The amount of spontaneous apoptosis predicts outcome in acute myeloid leukemia [abstract]. Blood. 2000;96:543a.